Skye Bioscience ends clinical development of SBI-100 Ophthalmic Emulsion

News
Article

All R&D for the drug will stop after the Phase 2a clinical trial failed to meet its primary endpoint of lowering IOP in patients with primary open-angle glaucoma.

(Image Credit: AdobeStock)

(Image Credit: AdobeStock)

Skye Bioscience announced it intends to discontinue clinical development and spending related to SBI-100 Ophthalmic Emulsion.

This decision follows the announcement that SBI-100 OE failed to meet its primary endpoint of lowering intraocular pressure in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) in a Phase 2a clinical trial.1

The company also stated in a press release that any R&D associated with SBI-100 OE will be discontinued, including its ophthalmology pipeline. All clinical development resources will be shifted to the company’s metabolic program.1

In the Phase 2a clinical trial of SBI-100 OE, 56 patients with elevated IOP diagnosed with POAG or OHT received dosing of 1.0% or 0.5% concentrations of SBI-100 OE or placebo. According to the company, “the study did not achieve a statistically significant improvement in IOP over placebo, [however], the drug was safe and all treated patients completed the study with no early discontinuations due to adverse events.”

Tu Diep, Skye’s Chief Development Officer talked about the results in a release from the company stating, “The results of this Phase 2a clinical trial of SBI-100 OE unfortunately did not meet our pre-set criteria for continuation and further development of this molecule as an alternative treatment for glaucoma and ocular hypertension. We will continue to evaluate the full data set and intend to publish findings. We thank the patients and investigators who supported our clinical investigation of SBI-100 OE in this study.”

Skye’s Phase 2 obesity clinical trial for its differentiated CB1 inhibitor, Nimacimab, is expected to begin dosing in Q3 2024.1

References:
  1. Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program. Press release; June 10, 2024. Accessed June 10, 2024. https://ir.skyebioscience.com/news-events/press-releases/detail/197/skye-concentrates-strategy-and-clinical-development-focus
Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.